Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for primary cutaneous B-cell lymphoma has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
24 publications have been identified in PubMed for primary cutaneous B-cell lymphoma. Research spans Case Report / Case Series (58%), Clinical Trial Publication (8%), and Basic Science / Preclinical (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 14 | 58% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Clinical study results |
2 |
8% |
Laboratory research | 2 | 8% |
Disease patterns and progression | 2 | 8% |
Other research | 1 | 4% |
Testing and diagnosis research | 1 | 4% |
Research summaries | 1 | 4% |
New treatment approaches | 1 | 4% |
Oertel M (2026). [PMID: 41824381](https://pubmed.ncbi.nlm.nih.gov/41824381/). *Blood*. [Clinical Trial Publication]
Cafaro A (2026). [PMID: 41743953](https://pubmed.ncbi.nlm.nih.gov/41743953/). *Frontiers in oncology*. [Case Report / Case Series]
Griss J (2026). [PMID: 41639106](https://pubmed.ncbi.nlm.nih.gov/41639106/). *Nature communications*. [Case Report / Case Series]
Taibjee SM (2026). [PMID: 41128751](https://pubmed.ncbi.nlm.nih.gov/41128751/). *The American Journal of dermatopathology*. [Case Report / Case Series]
Álvarez-Dávalos CM (2026). [PMID: 41728511](https://pubmed.ncbi.nlm.nih.gov/41728511/). *Cureus*. [Case Report / Case Series]
Markowska M (2026). [PMID: 41682819](https://pubmed.ncbi.nlm.nih.gov/41682819/). *Journal of clinical medicine*. [Case Report / Case Series]
Koumprentziotis IA (2025). [PMID: 39812237](https://pubmed.ncbi.nlm.nih.gov/39812237/). *The Australasian journal of dermatology*. [Epidemiology / Natural History]
Shah VK (2025). [PMID: 40305035](https://pubmed.ncbi.nlm.nih.gov/40305035/). *JAMA dermatology*. [Case Report / Case Series]
Fassanaro C (2025). [PMID: 40340188](https://pubmed.ncbi.nlm.nih.gov/40340188/). *Therapie*. [Case Report / Case Series]
de Araujo Melo E (2025). [PMID: 40214748](https://pubmed.ncbi.nlm.nih.gov/40214748/). *Acta diabetologica*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning primary cutaneous B-cell lymphoma
Updated Feb 4, 2026
Recent research indicates that indolent primary cutaneous B-cell lymphomas exhibit characteristics similar to persistent antigen reactions, lacking signs of dedifferentiation. This finding may influence future diagnostic and therapeutic strategies for this rare lymphoma subtype.